What Helixmith does

Helixmith is a privately held biotechnology company founded in 1996 and headquartered in Mapo, Seoul, South Korea, operating with a small team of 11–50 employees. The company is positioned within the regenerative medicine and cell therapy sector, with its primary disclosed focus on treatments for Critical Limb Ischemia (CLI) — a severe form of peripheral artery disease characterized by reduced blood flow, non-healing wounds, and risk of limb amputation. Third-party market research lists Helixmith among the participating companies in the global CLI therapy market alongside larger peers such as Baxter, Hemostemix, Caladrius Biosciences, Vericel Corporation, Ixaka, and Lifecells, in a market estimated at approximately USD 1,845M in 2023 with projected growth through 2034.

The company's therapeutic approach centers on cell-based interventions intended to restore microcirculation, promote tissue regeneration, and prevent amputation in CLI patients. No specific product candidates, clinical trial readouts, technology platform details, regulatory designations, manufacturing footprint, or pricing models are disclosed in the available data. The corporate website currently serves only a security verification page, indicating limited accessible company-level information, and there are no disclosed partners, distributors, or commercial agreements. Founder, CEO, and board member Jong Mook Kim is the only named member of the leadership team in the source material.

The business model cannot be determined from the available data. There is no disclosure of commercial revenue, licensing deals, or capital-raising events, and the firm has no identified customers, payors, or contracted channels. In aggregate, Helixmith presents as a small, founder-led, single-indication clinical-stage biotech with significant information gaps that prevent a more granular assessment of pipeline stage, capitalization, or commercial readiness.

Name

Helixmith

Website

https://helixmith.com

Company type

Private

Founded year

1996

Operating status

Operating

Headcount range

11–50 employees

Short description

Helixmith is a Seoul-based private biotechnology company developing cell therapy and regenerative medicine treatments for Critical Limb Ischemia, serving patients with severe peripheral artery disease and high unmet medical need.

Ownership category

akta.pro rank

Product category

Regenerative Medicine / Cell Therapy

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Cell & Tissue Banking (biobanking, cord blood/tissue) (HLAAAGAE)

akta.pro secondary industries

Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries) (HLAAAIAL), Recombinant Protein Therapeutics (enzymes, hormones, growth factors) (HLAAAAAB)

Keywords

• Regenerative medicine
• Cell therapy
• Gene therapy
• Biopharmaceuticals
• Tissue engineering

Headquarters

HQ city

Mapo

HQ country

South Korea

HQ region

Asia

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations

Core offering

Helixmith is a biotechnology company that develops regenerative medicine and cell/gene therapy treatments, with primary focus on therapies for Critical Limb Ischemia (CLI). The company's products are designed to restore microcirculation, promote tissue regeneration, and prevent limb amputation in patients with severe peripheral artery disease, addressing a clinical area with limited treatment options and high unmet medical need.

Differentiator

Problem solved

Functional benefit

Products and services

• Critical Limb Ischemia Cell Therapy Cell-based regenerative therapy in development to treat Critical Limb Ischemia (CLI), a severe form of peripheral artery disease, aimed at restoring blood flow, promoting tissue regeneration, and preventing limb amputation in patients with high unmet medical need.

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators1 record

Expansion highlights1 record

Direct peers

• Caladrius Biosciences: Clinical-stage cell therapy company developing regenerative medicine treatments, including programs in critical limb ischemia and other ischemic conditions. Directly comparable to Helixmith in modality, indication, and stage of development.
• Vericel Corporation: Commercial-stage cell therapy company focused on autologous cell-based treatments. Comparable in cell therapy modality and regenerative medicine positioning, and explicitly listed alongside Helixmith in the CLI market.
• Hemostemix Inc. Clinical-stage cell therapy company developing regenerative stem cell treatments for critical limb ischemia and other ischemic conditions. Directly comparable indication and modality.
• Ixaka: Cell and gene therapy company developing targeted, multi-cell therapies for serious diseases including ischemic conditions. Listed alongside Helixmith as a key company in the CLI market.
• Lifecells LLC: Company developing cell-based therapies for vascular conditions including critical limb ischemia. Directly listed alongside Helixmith in the CLI market research.

Broad incumbents

• Baxter International: Large global medical products and therapies company with significant presence in vascular and surgical therapies. Listed as a key player in the CLI market and represents a resource-heavy incumbent competitor.
• Mesoblast: Commercial and late-stage cell therapy company with a portfolio of mesenchymal lineage cell therapies for inflammatory and vascular diseases. Comparable modality with broader portfolio reach.

Emerging players

• Pluristem Therapeutics: Cell therapy company developing placenta-derived cell therapies for ischemic and inflammatory conditions including CLI. Comparable in regenerative cell therapy modality with partial indication overlap.
• Athersys: Clinical-stage regenerative medicine company developing MultiStem cell therapy for ischemic and inflammatory indications. Comparable in cell-based regenerative approach to vascular disease.
• Cytori Therapeutics: Cell therapy company developing autologous adipose-derived regenerative cell therapies for ischemic conditions. Modality-comparable peer with overlapping vascular disease focus.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Helixmith